PASO ROBLES, CA – August 17, 2017 – Greenbelt Resources Corporation (OTC: GRCO) has announced that Puration, Inc. (OTC: PURA) has selected its bioethanol to test for potential use in Puration’s patented CBD (cannabidiol) extraction method. Extraction methods commonly use ethanol but this will be the first time bioethanol produced from Greenbelt’s patent pending energy efficient membrane dehydration technology will be used in the process. Greenbelt produces its bioethanol from local waste streams including those produced by breweries and wineries.
Greenbelt has also developed a waste-to-energy technology known as ECOsystem that can be used as a global solution to address multiple types of food waste including those created on the farm and during the food processing. The process produces bioproducts including bioethanol, fertilizer, potable water and in some cases a high protein feed for human consumption designed to help meet the growing need for protein around the world. Greenbelt CEO Darren Eng anticipates that the ECOsystem technology will not only become a significant solution in the US but also in countries around the world. Currently Greenbelt is working on an initiative in Jakarta, Indonesia, The Indonesian initiative, JababECO, has broken ground. When the MOU was signed in April, it was celebrated by the attendance of Indonesian Vice President Jusuf Kalla and U.S. Vice President Mike Pence.
Extraction processes are used in many industries including the expanding legalized cannabiniod industry. Recent data shows that nearly 1.9 million North Americans are legally using cannabidiol to manage medical conditions as severe as polymorphic seizures and as common as chronic pain, while millions more are consuming it legally in adult-use states with little or no negative impact. Use is expected to grow exponentially as more states pass legal use laws.
Puration Inc. recently entered into an agreement with NCM Biotech, Inc. that is a substantial upgrade to the two companies previous joint venture agreement. NCM Biotech has licensed to PURA the right to utilize NCM Biotech’s patented ethanol extraction process to produce cannabidiol extracts for infusion into recreational, fitness, wellness, alternative medicine and beauty products. NCM Biotech exclusively owns U.S. Patent No. 9,199,960 which describes a “Method and apparatus for processing herbaceous plant materials…” NCM and PURA are combining efforts to build a state of the art extraction lab where the patented process can be further refined and tested not just improving the quality of PURA’s extracts for recreational, fitness, wellness, alternative medicine and beauty product uses, but also for pharmaceutical applications.
About Greenbelt Resources
Greenbelt Resources Corporation™ is an award-winning provider of sustainable energy production systems focused on delivering modular solutions that enable the localized processing of locally generated waste into locally consumed products. Greenbelt designs, develops and implements technology that makes the production of advanced biofuel reliable, practical and efficient. Controlled by proprietary automated controls, Greenbelt’s small-scale, end-to-end modular systems convert food, beverage and other cellulosic wastes into commercially viable advanced biofuels (bio-ethanol), animal feed, fertilizer and filtered water. For more information visit www.greenbeltresources.com.
Puration is engaged in the development of standardized and repeatable cannabidiol extraction processes that can deliver a consistent and high-quality concentrate for infusion into consumer food and beverage products that appeal to the recreational and wellness market segments. For more information visit www.purationinc.com.
This document includes certain statements, predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the supply and demand for biofuels, our ability to remain technologically competitive and other economic, competitive and technological factors involving the Company’s operations, markets, services, products and prices.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.